3D cell culture is an artificially created environment. 3D cell culture is a culture environment that allows biological cells to interact with their surroundings in all three dimensions. Cells grown in 3D cell culture exhibit similar properties of cells found in living organisms, in terms of cellular characteristics and behavior. This technique allows the cells to grow in their natural environment in an in vivo condition.
The global 3D cell culture market is estimated to be valued at US$ 2,604.3 million in 2020 and is expected to exhibit a CAGR of 23.4% during the forecast period (2020-2027).
Figure 1.Global 3D Cell Culture Market Share (%) in Terms of Value, By Technology 2020
Increasing product launches by key companies are expected to drive the market growth during the forecast period.
The increasing product launches of 3D cell cultures by regulatory authorities and key players, respectively are expected to drive the market growth over the forecast period. For instance, in January 2021, Jellagen Limited, a biotechnology company manufacturing high value Collagen Type 0 derived from jellyfish, announced the launch of JellaGel Hydrogel. 3-dimensaional hydrogels allow cells to grow and interact with all of its surroundings. Cells grown in a 3D model have proven to be more natural, with improved cell viability, morphology, proliferation, and differentiation.
Figure 2.Global 3D Cell Culture Market Share (%), by Application, 2020
Increasing R&D activities in 3D cell culture is expected to drive the market growth during the forecast period.
The increasing R&D activities in 3D cell culture is expected to aid in growth of the global 3D cell culture market, over the forecast period. For instance, in August 2020, researchers at Okayama University created a new 3D cell culture model of pancreatic cancer that closely mimics the 'fibrotic' tissue characteristically observed in patients.
|Base Year:||2019||Market Size in 2020:||US$ 2,604.3 Mn|
|Historical Data for:||2016 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||23.4%||2027 Value Projection:||US$ 11,335.1 Mn|
Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Lonza, Merck KGaA, 3D Biotek LLC, 3D Biomatrix, Inc., 3D Biomatrix, Inc., and REPROCELL Inc.
|Restraints & Challenges:||
Global 3D Cell Culture Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. The private healthcare is one of the sector, which has been majorly impacted by the pandemic. The lockdowns in various countries has created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatient’s visits, among others. Moreover, the pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the healthcare segment of various companies across the globe. This has led to closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of products. The COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Supply chain and manufacturing activities in India, China, U.S., and others have been disrupted due to global lockdowns. Whereas, countries such as Thailand, Indonesia, Singapore, and others are facing problems with transportation of drugs and medications. Thus, the pandemic is expected to slightly disrupt the R&D activities of the 3D cell culture market. However, currently the spread of coronavirus has spurred growth of 3D cell culture market, owing to increasing 3D cell culture for regeneration of 3D cell culture organs for understanding the mechanism of coronavirus infection.
Global 3D Cell Culture Market: Restraint
The major factors that hinder growth of the global 3D cell culture market include lack of consistency in 3D cell culture products. The lack of consistency between wells and batches of cell culture are the other major barriers in the adoption of 3D cell culture techniques. Researchers face several problems while inserting scaffold/ECM into microplate wells. This inconsistency in the products reduces the reproducibility of results and, thus, reduces the efficiency of the research.
Major players operating in the global 3D cell culture market include Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Lonza, Merck KGaA, 3D Biotek LLC, 3D Biomatrix, Inc., 3D Biomatrix, Inc., and REPROCELL Inc.
A 3D cell culture is an in-vitro technique wherein the cells can grow in an artificially created environment. These environments closely resemble to the architecture and functioning of the native tissue. 3D cell culture technique helps stimulate cell differentiation, proliferation, and migration by interacting with their three-dimensional surroundings, as they would in the in-vivo environment. As 3D cell cultures can mimic the structure, activity, and microenvironment of the in-vivo tissues, this technique has varied applications in the fields of drug screening, regenerative medicine, stem cell therapies, and cancer research and cell biology.
Key players operating in the global 3D cell culture market are focusing on adoption of inorganic growth strategies such as acquisitions, and collaborations, which are expected to drive the market growth during the forecast period. For instance, in August 2019, CELLINK AB entered an agreement with the owners of Cytena GmbH to acquire all Cytena shares for a purchase price of US$ 36.4 million. The acquisition is in line with CELLINK’s commercial strategy, strengthening CELLINK’s product offering and providing a more complete 3D cell culturing solution. Furthermore, in June 2018, Greiner Bio-One North America, Inc. acquired 3D Cell Culture Technology assets previously owned by Nano 3D Biosciences, Inc. This strategic acquisition aims for the potential growth in the 3D cell culture market with laboratories and research facilities utilizing this new technology daily to find cures for disease and improve the existing cell culture methodology. Furthermore, in December 2019, Allevi and Lonza announced a strategic collaboration to bring the elements needed for 3D bioprinting together. Combining Lonza’s primary cells and media with Allevi’s 3D bioprinters and bioink production capabilities will empower researchers with the tools needed for plug-and-play bioprinting.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.